PDF(Pubmed)
Abstract：
Methemoglobinemia is a potentially life-threatening, rare condition in which the oxygen-carrying capacity of hemoglobin is diminished. We present the case of a 3-year-old boy treated for T-cell acute lymphoblastic leukemia (T-ALL) who developed methemoglobinemia (MetHb 57.1%) as a side effect of ifosfamide administration. Due to his critical condition, the patient was transferred to the intensive care unit (ICU). The therapy included methylene blue administration, an exchange transfusion, catecholamine infusion, and steroids. Improving the general condition allowed for continuing chemotherapy without ifosfamide and completion of the HR2 block. Vigilance for methemoglobinemia as a very rare side effect should be widespread when using ifosfamide in the treatment protocols.
摘要：
高铁血红蛋白血症是一种潜在的危及生命的疾病,血红蛋白携氧能力减弱的罕见情况。我们介绍了一个3岁男孩接受T细胞急性淋巴细胞白血病（T-ALL）治疗的案例，该男孩因服用异环磷酰胺而出现高铁血红蛋白血症（MetHb57.1％）。由于他的病情危急,患者被转移至重症监护病房(ICU).治疗包括亚甲蓝给药，交换输血，儿茶酚胺输注,和类固醇。改善一般状况，可以在没有异环磷酰胺的情况下继续化疗，并完成HR2阻断。在治疗方案中使用异环磷酰胺时应广泛警惕高铁血红蛋白血症作为一种非常罕见的副作用。
